Improving expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

被引：0
|
作者：
不详
机构：
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2011年 / 90卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：198 / 198
页数：1
相关论文
共 50 条
  • [1] CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
    Savoldo, Barbara
    Ramos, Carlos Almeida
    Liu, Enli
    Mims, Martha P.
    Keating, Michael J.
    Carrum, George
    Kamble, Rammurti T.
    Bollard, Catherine M.
    Gee, Adrian P.
    Mei, Zhuyong
    Liu, Hao
    Grilley, Bambi
    Rooney, Cliona M.
    Heslop, Helen E.
    Brenner, Malcolm K.
    Dotti, Gianpietro
    JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (05): : 1822 - 1826
  • [2] Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma
    Svoboda, Jakub
    Rheingold, Susan R.
    Gill, Saar I.
    Grupp, Stephan A.
    Lacey, Simon F.
    Kulikovskaya, Irina
    Suhoski, Megan M.
    Melenhorst, J. Joseph
    Loudon, Brandon
    Mato, Anthony R.
    Nasta, Sunita Dwivedy
    Landsburg, Daniel J.
    Youngman, Matthew R.
    Levine, Bruce L.
    Porter, David L.
    June, Carl H.
    Schuster, Stephen J.
    BLOOD, 2018, 132 (10) : 1022 - 1026
  • [3] Chimeric Antigen Receptor-Modified T Cells in CLL
    Yeh, Chi Chun
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (20): : 1937 - 1937
  • [4] Pharmacology of Chimeric Antigen Receptor-Modified T Cells
    Song, Edward Z.
    Milone, Michael C.
    ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 61, 2021, 2021, 61 : 805 - 829
  • [5] Chimeric Antigen Receptor-Modified T Cells in CLL REPLY
    Urba, Walter J.
    Longo, Dan L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (20): : 1939 - 1939
  • [6] Chimeric antigen receptor-modified T cells strike back
    Frigault, Matthew J.
    Maus, Marcela V.
    INTERNATIONAL IMMUNOLOGY, 2016, 28 (07) : 355 - 363
  • [7] A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma
    Chen, Xinfeng
    Li, Xin
    Liu, Yanfen
    Zhang, Zhen
    Zhang, Xudong
    Huang, Jianmin
    Li, Hong
    Li, Feng
    Zhang, Lei
    Li, Ling
    Wu, Xiaolong
    Ma, Wang
    Sun, Zhenchang
    Yu, Hui
    Zhou, Zhiyuan
    Feng, Xiaoyan
    Cui, Kang
    Li, Zhaoming
    Zhang, Hongling
    Zeng, Ying
    Wan, Xiaochun
    Chen, Youhai H.
    Zhang, Mingzhi
    Zhang, Yi
    IMMUNOTHERAPY, 2020, 12 (10) : 681 - 696
  • [8] PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells
    Wenting Zheng
    Carol E. O’Hear
    Rajshekhar Alli
    Jacob H. Basham
    Hossam A. Abdelsamed
    Lance E. Palmer
    Lindsay L. Jones
    Ben Youngblood
    Terrence L. Geiger
    Leukemia, 2018, 32 : 1157 - 1167
  • [9] PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells
    Zheng, Wenting
    O'Hear, Carol E.
    Alli, Rajshekhar
    Basham, Jacob H.
    Abdelsamed, Hossam A.
    Palmer, Lance E.
    Jones, Lindsay L.
    Youngblood, Ben
    Geiger, Terrence L.
    LEUKEMIA, 2018, 32 (05) : 1157 - 1167
  • [10] Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
    Grupp, Stephan A.
    Kalos, Michael
    Barrett, David
    Aplenc, Richard
    Porter, David L.
    Rheingold, Susan R.
    Teachey, David T.
    Chew, Anne
    Hauck, Bernd
    Wright, J. Fraser
    Milone, Michael C.
    Levine, Bruce L.
    June, Carl H.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (16): : 1509 - 1518
12345